These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35611205)

  • 1. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma.
    Yao M; Yang JL; Wang DF; Wang L; Chen Y; Yao DF
    World J Clin Cases; 2022 Apr; 10(11):3321-3333. PubMed ID: 35611205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Carcinoembryonic type specific markers and liver cancer immunotherapy].
    Yao M; Yang JL; Wang L; Yao DF
    Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):466-470. PubMed ID: 32660172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma.
    Yao M; Fang RF; Xie Q; Xu M; Sai WL; Yao DF
    World J Gastrointest Oncol; 2024 Jun; 16(6):2350-2361. PubMed ID: 38994143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
    Song S; Bai M; Li X; Gong S; Yang W; Lei C; Tian H; Si M; Hao X; Guo T
    Expert Rev Mol Diagn; 2022 Mar; 22(3):361-378. PubMed ID: 35234564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy.
    Huang SL; Wang YM; Wang QY; Feng GG; Wu FQ; Yang LM; Zhang XH; Xin HW
    Front Genet; 2021; 12():691391. PubMed ID: 34306031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific molecular markers in hepatocellular carcinoma.
    Yao DF; Dong ZZ; Yao M
    Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):241-7. PubMed ID: 17548245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.
    Enguita-Germán M; Fortes P
    World J Hepatol; 2014 Oct; 6(10):716-37. PubMed ID: 25349643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis.
    Zheng W; Yao M; Wu M; Yang J; Yao D; Wang L
    J Transl Med; 2020 Feb; 18(1):81. PubMed ID: 32059741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules.
    Gutierrez JA; Gish RG
    Transl Cancer Res; 2013 Dec; 2(6):460-471. PubMed ID: 26504748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aquaporin 9 inhibits growth and metastasis of hepatocellular carcinoma cells via Wnt/β-catenin pathway.
    Liao S; Chen H; Liu M; Gan L; Li C; Zhang W; Lv L; Mei Z
    Aging (Albany NY); 2020 Jan; 12(2):1527-1544. PubMed ID: 31969493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
    Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
    Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
    Huynh H; Ong R; Goh KY; Lee LY; Puehler F; Scholz A; Politz O; Mumberg D; Ziegelbauer K
    Int J Oncol; 2019 Mar; 54(3):1123-1133. PubMed ID: 30747223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of WNT/β-catenin signaling for hepatocellular carcinoma.
    Asaoka Y; Tanaka A
    Glob Health Med; 2020 Oct; 2(5):269-272. PubMed ID: 33330820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.
    Li Q; Sun M; Wang M; Feng M; Yang F; Li L; Zhao J; Chang C; Dong H; Xie T; Chen J
    Cancer Sci; 2021 May; 112(5):1695-1706. PubMed ID: 33605517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
    Lei T; Zhu X; Zhu K; Jia F; Li S
    Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.